infinitusbio, powered by KHAi.netinfinitusbio, powered by KHAi.net

The Intelligence Company for the Molecule Economy.

Our Macro-connectionist Multi-Agent AI simulates drugs inside patients’ cells to reveal where they work, in whom, and why: a mechanistic read no model trained on history can make.

No training. No inherited bias. No hallucinations.

Fully mechanisticDeterministic

Read the thesis →

Reading with DebiopharmOncovitaJ. Craig Venter Institute Further partners under NDA

The read

One read. Three answers.

Bring a molecule at any stage: discovery, preclinical, clinical or a whole portfolio. We simulate it inside patients’ cells* and tell you:

  1. 1

    Will it work, where and in whom?

    The indications and patient cell states where the molecule responds, and the mechanism behind it.

  2. 2

    Is it better than the standard of care?

    Head to head with the standard of care and other drugs, in the same digitally cloned cells.

  3. 3

    If not on its own, then with what?

    The combinations with the standard of care or other drugs that give it a path to approval.

* Limited inputs from public or proprietary data are sufficient to digitally clone patient cells and biopsies.

How it works

The unbiased intelligence that reads any molecule, mechanistically.

01 Molecule in02 Cell responds03 Read sealed

Others predict odds from history. infinitusbio's Macro-connectionist Multi-Agent AI digitally clones a patient's cell, treats the clone with the drug, and reads the mechanism: which indications, which patients, and why. Odds tell you how often. Mechanism tells you why.

The Ledger

Seal No. 010 · a clinical-stage molecule, a public readout, one call. See the Ledger.

See the next five quarters →